SCHEMBL4091844

SCHEMBL4091844

Cc1cc(NC(=O)c2ccc3c(c2)CCNC3)nn1Cc1cc(Cl)ccc1OCC(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29761900 1.00 PTGER1 (1.00) PTGER1
Hydrochloric Acid SCHEMBL4104578 0.99 PTGER1 (1.00) PTGER1
SCHEMBL13693324 0.95 PTGER1 (0.98) PTGER1
Hydrochloric Acid SCHEMBL4096755 0.95 PTGER1 (1.00) PTGER1
SCHEMBL3056778 0.91 PTGER1 (0.84) PTGER1
Hydrochloric Acid SCHEMBL3056914 0.90 PTGER1 (0.84) PTGER1
SCHEMBL3578834 0.90 PTGER1 (0.81) PTGER1
SCHEMBL3058104 0.90 PTGER1 (0.81) PTGER1
Hydrochloric Acid SCHEMBL3049776 0.89 PTGER1 (0.82) PTGER1
Hydrochloric Acid SCHEMBL3583126 0.89 PTGER1 (0.82) PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239845-A1 PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS CONWAY ELIZABETH ANN 2009-09-24 US claimed
US-20180153830-A1 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2018-06-07 US disclosed
US-20180153830-A1 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2018-06-07 US disclosed
US-20170027890-A1 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2017-02-02 US disclosed
US-20170027890-A1 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2017-02-02 US disclosed
US-20170027890-A1 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2017-02-02 US disclosed
US-9456998-B2 Selective inhibitors of undifferentiated cells YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2016-10-04 US disclosed
US-9456998-B2 Selective inhibitors of undifferentiated cells YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2016-10-04 US disclosed
US-9456998-B2 Selective inhibitors of undifferentiated cells YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2016-10-04 US disclosed
CN-104768549-A Selective inhibitors of undifferentiated cells YISSUM RES DEV CO 2015-07-08 CN disclosed
US-20150148359-A1 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2015-05-28 US disclosed
US-20150148359-A1 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2015-05-28 US disclosed
US-20150148359-A1 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2015-05-28 US disclosed
EP-2852387-A2 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2015-04-01 EP disclosed
WO-2013175474-A2 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2013-11-28 WO disclosed
WO-2013175474-A2 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2013-11-28 WO disclosed
US-20090239845-A1 PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS CONWAY ELIZABETH ANN 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239845-A1 PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS PTGER1, PTGDR, PTGIR PTGER1 1/4885
US-20180153830-A1 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS MCL1, MKI67, SCD PTGER1 732/4885
US-20170027890-A1 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS MCL1, MKI67, SCD PTGER1 732/4885
US-20150148359-A1 SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS MCL1, MKI67, SCD PTGER1 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.